Showing results (191-200 of 209) with videos related to
Sort By:
Pageof 21
Iscience|February 6, 2024
Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer baseHongying Duan, Angela R Corrigan, Cheng Cheng, et al.Science (New York, N.Y.)|October 7, 2016
Rapid development of a DNA vaccine for Zika virusKimberly A Dowd, Sung-Youl Ko, Kaitlyn M Morabito, et al.Plos Neglected Tropical Diseases|June 20, 2017
Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaquesRebecca Broeckel, Julie M Fox, Nicole Haese, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 28, 2020
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 InfectionWafaa B Alsoussi, Jackson S Turner, James B Case, et al.Cell|June 20, 2020
A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing AntibodiesAhmed O Hassan, James Brett Case, Emma S Winkler, et al.JAMA|April 15, 2020
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical TrialGrace L Chen, Emily E Coates, Sarah H Plummer, et al.Nature|February 3, 2017
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccinationNorbert Pardi, Michael J Hogan, Rebecca S Pelc, et al.Nature Microbiology|October 14, 2025
Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza virusesAlexandra A Abu-Shmais, Gray Freeman, Adrian Creanga, et al.Lancet (London, England)|December 9, 2017
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trialsMartin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, et al.The Journal of Experimental Medicine|August 18, 2025
Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodiesRyan S Roark, Rumi Habib, Jason Gorman, et al.Pageof 21